Mice administered IL-1β develop hypercalcemia and display increased osteoclast numbers, and treatment with chimeric osteoprotegerin (OPG; a RANKL antagonist) reduced hypercalcemia and osteoclast number [26]. Here, TNFSF11 is linked to hypercalcemia disease.